GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

relcobatinib   Click here for help

GtoPdb Ligand ID: 14371

Synonyms: compound 95 [WO2022076975]
Compound class: Synthetic organic
Comment: The chemical structure for this compound was obtained from WHO INN proposed list 134 (Feb 2026) in which relcobatinib is described as a tyrosine-protein kinase ABL1 allosteric inhibitor with antineoplastic potential. The compound is claimed as compound 95 in patent WO2022076975 (Enliven Therapeutics) [2]. There is one declared BCR-ABL lead in Enliven's development pipeline, so we surmise that relcobatinib is the INN match for ELVN-001. ELVN-001 is intended to target oncogenic BCR-ABL fusion gene products that drive chronic myeloid leukemia (CML). As an allosteric inhibitor it retains activity against the common gatekeeper mutation T315I in ABL1.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 87.88
Molecular weight 371.37
XLogP 0.18
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CN1C(=CC2=C1C=NC(=C2)NC(=O)[C@@H]3C[C@@H]3F)C4=C(N=CN=C4OC([2H])([2H])[2H])OC([2H])([2H])[2H]
Isomeric SMILES CN1C(=CC=2C1=CN=C(NC(=O)[C@H]3[C@@H](F)C3)C2)C=4C(OC([2H])([2H])[2H])=NC=NC4OC([2H])([2H])[2H]
InChI InChI=1S/C18H18FN5O3/c1-24-12(15-17(26-2)21-8-22-18(15)27-3)4-9-5-14(20-7-13(9)24)23-16(25)10-6-11(10)19/h4-5,7-8,10-11H,6H2,1-3H3,(H,20,23,25)/t10-,11+/m1/s1/i2D3,3D3
InChI Key SULRARRXFNUQFC-KQLZAONFSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
ELVN-001 was progressed as a clinical candidate for the treatment of CML [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05304377 A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia Phase 1 Interventional Enliven Therapeutics
NCT06787144 ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants Phase 1 Interventional Enliven Therapeutics